Production and regulatory issues for theranostics

Area of Science:

• Oncology
• Nuclear Medicine
• Radiopharmaceutical Therapy

Background:

• Theranostics has significantly advanced cancer care in the past decade.
• Approved theranostic agents are now available for neuroendocrine tumors and prostate cancer.
• Global access to these innovative treatments is crucial for patient benefit.

Purpose of the Study:

• To explore factors affecting the accessibility and availability of theranostic radiopharmaceuticals.
• To identify supply chain and regulatory challenges impacting theranostic treatment delivery.
• To ensure equitable global access to advanced cancer therapies.

Main Methods:

• Review of current literature on theranostic radiopharmaceutical supply chains.
• Analysis of regulatory landscapes impacting radiopharmaceutical approval and distribution.
• Case study examination of access issues in different global regions.

Main Results:

• Significant disparities exist in global access to theranostic radiopharmaceuticals.
• Supply chain complexities and manufacturing limitations hinder widespread availability.
• Varying national regulatory frameworks create barriers to treatment adoption.

Conclusions:

• Addressing supply and regulatory challenges is essential for expanding theranostic benefits.
• International collaboration is needed to harmonize regulations and improve supply chains.
• Ensuring global access to theranostic radiopharmaceuticals is critical for equitable cancer care.